Concepedia

Differential frequency in <scp>imaging‐based</scp> outcome measurement: Bias in <scp>real‐world</scp> oncology <scp>comparative‐effectiveness</scp> studies

Blythe Adamson, Xinran Ma, Sandra D. Griffith, Elizabeth Sweeney, Somnath Sarkar, Ariel B. Bourla

Pharmacoepidemiology and Drug Safety · 2021 · 18 citations · 26 references

DOIFull text

Open access

Abstract

This study provided evidence that the frequency of imaging assessments to detect disease progression can differ by treatment type in real-world patients with cancer and may induce some bias in comparative-effectiveness studies in some situations.

References

26

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 9.8K citations · Full text

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

, , +8

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

, , +9

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al. · Journal of the National Comprehensive Cancer Network · 2019 · 997 citations · Full text

, , +15